Press Releases
Rejuvenate Bio Announces Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in the Journal Cellular Reprogramming
Rejuvenate Bio Announces Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in the Journal Cellular Reprogramming
Rejuvenate Bio Announces Preclinical Data for Gene Therapy Candidate RJB-0402 for the Treatment of Arrhythmogenic Cardiomyopathy
A single dose of RJB-0402 was able to significantly improve cardiac function, preserve cardiac structure, and dramatically reduce premature ventricular contractions (PVCs) to normal levels.
New Preclinical Research Evaluating Cellular Reprogramming for Age Reversal
Rejuvenate Bio announced new preclinical research published to the preprint server bioRxiv that evaluates how partial reprogramming could be a potential treatment in the elderly to reverse age-associated diseases and potentially extend human lifespan.
Rejuvenate Bio Appoints Deborah Ascheim, M.D., as Chief Medical Officer
Rejuvenate Bio today announced the appointment of Deborah Ascheim, M.D., as Chief Medical Officer. In this inaugural role, she will oversee clinical development and regulatory activities and lead the strategy, design and execution of clinical trials to advance a pipeline of gene therapy programs for chronic age-related diseases.
Rejuvenate Bio Announces Expansion of Scientific Advisory Board
Newly appointed members include Hugh Calkins, M.D., Stephen Chelko, Ph.D., and Dr. Elif Oral, M.D
Phibro Animal Health Corporation and Rejuvenate Bio Announce Agreement to Develop Gene Therapy for Mitral Valve Disease in Canines
Phibro Animal Health Corporation (Nasdaq:PAHC) and Rejuvenate Bio, Inc. announced a collaboration for the development and commercialization of a gene therapy for Mitral Valve Disease (MVD) in canines (dogs).
Rejuvenate Bio Raises Over $10M in Series A Funding for Gene Therapy Aging Treatment
Rejuvenate Bio announced today that it has raised over $10 million in a Series A funding round led by Kendall Capital Partners, a Boston-based firm focused on early-stage biotech companies. Additional investors in round include gene therapy pioneer Dr. Katherine High, V Capital, KdT Ventures, and Digitalis Ventures…